Fate Therapeutics (NASDAQ:FATE) Upgraded at Wedbush

Wedbush upgraded shares of Fate Therapeutics (NASDAQ:FATE) from a neutral rating to an outperform rating in a research report sent to investors on Monday morning, MarketBeat.com reports. They currently have $7.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $5.00. Wedbush also issued estimates for Fate Therapeutics’ Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.24) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.28) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($1.63) EPS and FY2029 earnings at ($1.65) EPS.

Other research analysts have also recently issued reports about the stock. Wells Fargo & Company decreased their price objective on shares of Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating for the company in a report on Wednesday, August 13th. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a report on Monday. Wall Street Zen raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Fate Therapeutics in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Fate Therapeutics has an average rating of “Hold” and a consensus price target of $3.70.

Fate Therapeutics Stock Down 10.1%

FATE opened at $1.34 on Monday. The firm has a 50 day moving average price of $1.21 and a 200-day moving average price of $1.19. Fate Therapeutics has a twelve month low of $0.66 and a twelve month high of $3.50. The stock has a market capitalization of $154.54 million, a price-to-earnings ratio of -0.92 and a beta of 2.34.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. Fate Therapeutics had a negative net margin of 2,025.05% and a negative return on equity of 50.95%. The firm had revenue of $1.91 million during the quarter, compared to analysts’ expectations of $1.16 million. As a group, analysts expect that Fate Therapeutics will post -1.63 earnings per share for the current year.

Hedge Funds Weigh In On Fate Therapeutics

Hedge funds have recently modified their holdings of the company. Savant Capital LLC bought a new position in shares of Fate Therapeutics in the second quarter worth approximately $27,000. Bridgeway Capital Management LLC bought a new position in shares of Fate Therapeutics in the second quarter worth approximately $28,000. CWM LLC boosted its position in shares of Fate Therapeutics by 899.6% in the first quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 37,290 shares during the period. Headlands Technologies LLC bought a new position in shares of Fate Therapeutics in the second quarter worth approximately $56,000. Finally, Caption Management LLC bought a new position in shares of Fate Therapeutics in the first quarter worth approximately $45,000. 97.54% of the stock is currently owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.